Biosketch Raquel Pérez-López

Raquel Pérez-López

rperez@vhio.net

Lloc actual

Cap de grup, Grup de Radiòmica del VHIO

Formació acadèmica

2017: Doctora en Medicina per la Universitat Autònoma de Barcelona (Espanya).
2013-2017: Beca de recerca clínica al Royal Marsden NHS Trust i l’Institut de Recerca del Càncer, Londres (Regne Unit).
2011: Pràctiques clíniques al Barts Health NHS Trust, Londres (Regne Unit).
2010-2011: Màster en Recerca Clínica a la Universitat de Barcelona (Espanya).
2007-2011: Formació d’especialista en radiologia a l’Hospital Universitari de Bellvitge, Barcelona (Espanya).
2000-2006: Llicenciada en Medicina per la Universitat de Barcelona (Espanya).

Àrees de recerca

Identificació, validació i qualificació clínica de biomarcadors d’imatge predictius i de resposta per a teràpies dirigides i immunoteràpia contra el càncer.
Avaluació de la resposta diferencial a les teràpies dirigides amb biomarcadors d’imatge per a estudis d’evolució tumoral i mecanismes de resistència.
Desenvolupament i optimització de seqüències funcionals de ressonància magnètica.
Integració de l’enginyeria i el desenvolupament de programari per a l’anàlisi d’imatges i l’extracció de biomarcadors d’imatge quantificables.

Premis i beques

Premi Investigadora Jove de l’Institut Català de la Salut (ICS). 2022
Premi del Programa de Talents Investigadors de la Fundació CRIS 2020.
Premi per a Joves Investigadors de la Fundació del Càncer de Pròstata (PCF) 2018 .
Premi del programa «Invest in Youth» de la Societat Europea de Radiologia (ESR) 2017.
Beca de l’Escola Europea de Radiologia (ESOR) 2011.

Projectes

TANGERINE: Artificial-intelligence-based end-to-end prediction of cancer immunotherapy response . TRANSCAN Program (Spanish Association against Cancer and Instituto de Salud Carlos III). 2023-2025.
ODELIA: An Open Consortium for Decentralized Medical Artificial Intelligence. H2020 Program (European Commission). 2023-2028
MARION: Multimodal biomarkers for precise management of metastatic prostate cancer. Proyectos de colaboración público-privada (Industry Ministry Spanish Government). 2023-2025.
PRECISE: Deciphering colon cancer heterogeneity with machine learning and precision imaging. Instituto de Salud Carlos III. 2022-2025.
Tumoral senescence induced by anti-cancer therapies constitutes a novel prognostic biomarker and a therapeutic target. Fundación Científica Asociación Española Contra el Cáncer-Proyectos Coordinados. 2021-2026.
CCE-DART: Building Data Rich Clinical Horizon 2020 Program – European Commission. VHIO. 2021-2026.
Unraveling the tumor immunophenotype with deep-learning based FERO Foundation Research Fellowship.
PREdICT: Personalized REsponse Imaging biomarker for Cancer CRIS Cancer ResearchTalent Program from the CRIS Foundation, AstraZeneca PoC Award.
PrecIMet: precision imaging for bone metastases. Fundació La Marató de
Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Horizon 2020-Innovative Medicine Initiatives (IMI2-Call4; 831514)
Validación clínica de la resonancia de cuerpo completo con difusión en pacientes con cáncer de próstata resistente a la castración y metástasis óseas. Instituto de Salud Carlos III-Investigación en Salud (PI18/01395).
Detection of genetic abnormalities using persistent homology in radiomics. European Commission funded ATTRACT program. 2019- 2020.
Clinical Qualification of DNA Repair Defects as Biomarkers in Metastatic Prostate Cancer Using Integrated Genomics and Tissue-Based Functional Assays. Department of Defense (DoD) from the USA Impact Award.

Publicacions científiques més rellevants

Ghaffari Laleh N, Ligero M, Perez-Lopez R, Kather JN. Facts and Hopes on the Use of Artificial Intelligence for Predictive Immunotherapy Biomarkers in Cancer. Clin Cancer Res. 2023 Jan 17;29(2):316-323.

Ligero, M., Hernando, J., Delgado, E. et al. Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial. BJC Rep 1, 9 (2023).

Ligero M, Simó M, Carpio C, Iacoboni G, Balaguer-Montero M, Navarro V, Sánchez-Salinas MA, Bobillo S, Marín-Niebla A, Iraola-Truchuelo J, Abrisqueta P, Sala-Llonch R, Bosch F, Perez-Lopez R, Barba P. PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma. EJHaem. 2023 Sep 11;4(4):1081-1088.

Ramlee S, Hulse D, Bernatowicz K, Pérez-López R, Sala E, Aloj L. Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study. Cancers (Basel). 2022 Jul 27;14(15):3656.

Grussu F, Bernatowicz K, Casanova-Salas I, Castro N, Nuciforo P, Mateo J, Barba I, Perez-Lopez R. Diffusion MRI signal cumulants and hepatocyte microstructure at fixed diffusion time: Insights from simulations, 9.4T imaging, and histology. Magn Reson Med. 2022 Jul;88(1):365-379.

Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, Randon G, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, Pietrantonio F, Dienstmann R, Tabernero J, Toledo RA. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat Med. 2022 Oct;28(10):2162-2170.

Pons-Escoda A, Garcia-Ruiz A, Naval-Baudin P, Grussu F, Fernandez JJS, Simo AC, Sarro NV, Fernandez-Coello A, Bruna J, Cos M, Perez-Lopez R, Majos C. Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis. Eur Radiol. 2022 Jun;32(6):3705-3715.

Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors. Radiology. 2020 Jan 26.
Ligero M, Jordi-Ollero O, Bernatowicz K, Garcia A, Delgado-Muñoz E, Leiva D, Mast R, Suarez C, Sala-Llonch R, Calvo N, Escobar M, Navarro-Martin A, Villacampa G, Dienstmann R, Perez-Lopez R. Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large scale data analysis. Eur Radiol. 2020 Sep 9.
Garcia-Ruiz A, Naval-Baudin P, Ligero M, Pons-Escoda A, Bruna J, Plans G, Calvo N, Cos M, Majós C, Perez-Lopez R. Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastomas. Sci Rep. Dec 2020.
Pons A, Garcia A, Naval P, Cos M, Vidal N, Plans G, Bruna J, Perez-Lopez R, Majós
Presurgical Identification of Primary Central Nervous System Lymphoma with Normalized Time-Intensity Curve: A Pilot Study of a New Method to Analyze DSC-PWI. AJNR Am J Neuroradiol. 2020 Oct;41(10):1816-1824.
Yap TA, O’Carrigan B, Penney MS, Lim JS, Brown JS, Miguel Luken MJ, Tunariu N, Perez-Lopez R, Nava Rodrigues D, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020 Jun 22;JCO1902404.
Deroose CM, Gheysens O, Perez-Lopez R. PET or MRI to improve evaluation of response in clinical trials? Lancet Oncol. 2019 Aug;20(8):1060-1062.
Perez-Lopez R, Tunariu N, Padhani A, Oyen W, Fanti S, Vargas HA, Omlin A, Morris MJ, De Bono J, Koh DM. Imaging diagnosis and follow-up of advanced prostate cancer: Clinical perspectives and state-of-the-art. Radiology. 2019 Aug;292(2):273-286.
Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, Messina C, Sumanasuriya S, Bianchini D, Barrero M, Petremolo A, Zafeiriou Z, Fontes MS, Perez-Lopez R, Tunariu N, Fulton BA, Jones R, McGovern UB, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS. Genomics of lethal prostate cancer at diagnosis and castration-resistance. J Clin Invest. 2019 Dec 24. pii: 132031.
Matos I, Martin-Liberal J, Garcia-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Brana I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Élez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodon J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E. Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria. Clin Cancer Res. 2019 Nov 22. pii: clincanres.2226.2019.
Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife R, Koh DM, Kaye S, de Bono J, Tunariu N and Yap T. High Frequency of Radiological Differential Responses with Poly (ADP-ribose) Polymerase Inhibitor Therapy. Oncotarget. In press, October 2017.
Perez-Lopez R, Nava Rodrigues D, Figueiredo I, Mateo J, Collins D, Koh DM, de Bono J, Tunariu Multi-Parametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation with Bone Biopsy Histological and Molecular Features. Invest Radiol. 2017 Sep 12. doi: 10.1097/RLI.0000000000000415.
Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N. Diffusion-weighted Imaging as a Treatment Response Biomarker Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology. 2017 Apr; 283(1):168-177. doi: 10.1148/radiol.2016160646. Epub 2016 Nov 22.
Perez-Lopez R, Lorente D, Blackledge MD, Collins DJ, Mateo J, Bianchini D, Omlin A, Zivi A, Leach MO, de Bono JS, Koh DM, Tunariu N. Volume of Bone Metastasis Assessed with Whole-Body Diffusion- weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology. 2016 Jul; 280(1):151-60. doi: 10.1148/radiol.2015150799. Epub 2016 Jan 25.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A’Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21;161(5):1215-28. doi: 10.1016/j.cell.2015.05.001.
Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS; TOPARP-A investigators. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov. 2017 Apr 27. pii: CD-17-0261. doi: 10.1158/2159-8290.CD-17-0261.
Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res. 2015 Oct 15;21(20):4586-96. doi: 10.1158/1078-0432.CCR-15-0584.

Totes les publicacions

Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, Randon G, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, Pietrantonio F, Dienstmann R, Tabernero J, Toledo RA. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF^V600Emetastatic colorectal cancer. Nat Med. 2022 Oct;28(10):2162-2170.

Ramlee S, Hulse D, Bernatowicz K, Pérez-López R, Sala E, Aloj L. Radiomic Signatures Associated with CD8⁺Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study. Cancers (Basel). 2022 Jul 27;14(15):3656.

Sedlaczek OL, Kleesiek J, Gallagher FA, Murray J, Prinz S, Perez-Lopez R, Sala E, Caramella C, Diffetock S, Lassau N, Priest AN, Suzuki C, Vargas R, Giandini T, Vaiani M, Messina A, Blomqvist LK, Beets-Tan RGH, Oberrauch P, Schlemmer HP, Bach M; CCE – Imaging Task Force. Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force. Eur Radiol. 2022 Dec;32(12):8617-8628.

Zunder SM, Perez-Lopez R, de Kok BM, Raciti MV, van Pelt GW, Dienstmann R, Garcia-Ruiz A, Meijer CA, Gelderblom H, Tollenaar RA, Nuciforo P, Wasser MN, Mesker WE. Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. Eur J Radiol. 2020 Oct 13;133:109345. doi: 10.1016/j.ejrad.2020.109345. Epub ahead of print. PMID: 33120239.
Perez-Lopez, D. Roda , B. Jimenez , J. Brown, J. Mateo, S. Carreira, Lopez J, Banerji U, Molife R, Koh DM, Kaye S, de Bono J, Tunariu N and Yap T. et al. High Frequency of Radiological Differential Responses with Poly (ADP-ribose) Polymerase Inhibitor Therapy. 61. ISSN 1949-2553. doi:10.18632/oncotarget.22303.
Perez-Lopez R, Nava Rodrigues D, Figueiredo I, Mateo J, Collins D, Koh DM, de Bono J, Tunariu Multi-Parametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation with Bone Biopsy Histological and Molecular Features. Invest Radiol. 2017 Sep 12. doi: 10.1097/RLI.0000000000000415.
Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS; TOPARP-A investigators. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov. 2017 Apr 27. pii: CD-17-0261. doi: 10.1158/2159-8290.CD-17-0261.
Bianchini D, Lorente D, Rescigno P, Zafeiriou Z, Psychopaida E, O’Sullivan H, Alaras M, Kolinsky M, Sumanasuriya S, Sousa Fontes M, Mateo J, Perez Lopez R, Tunariu N, Fotiadis N, Kumar P, Tree A, Van As N, Khoo V, Parker C, Eeles R, Thompson A, Dearnaley D, de Bono JS. Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. Clin Genitourin Cancer. 2017 Apr 26. pii: S1558-7673(17)30097-6. doi: 10.1016/j.clgc.2017.04.013.
Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N. Diffusion-weighted Imaging as a Treatment Response Biomarker Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology. 2017 Apr; 283(1):168-177. doi: 10.1148/radiol.2016160646. Epub 2016 Nov 22.
Lorente D, Omlin A, Zafeiriou Z, Nava-Rodrigues D, Pérez-López R, Pezaro C, Mehra N, Sheridan E, Figueiredo I, Riisnaes R, Miranda S, Crespo M, Flohr P, Mateo J, Altavilla A, Ferraldeschi R, Bianchini D, Attard G, Tunariu N, de Bono J. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. Clin Genitourin Cancer. 2016 May. doi: 10.1016/j.clgc.2016.04.016.
Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, Zafeiriou Z, Sumanasuriya S, Smith AD, Mehra N, Jayaram A, Perez-Lopez R, Mateo J, Parker C, Dearnaley DP, Tunariu N, Reid A, Attard G, de Bono JS. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 Nov; 70(5):724-731. doi: 10.1016/j.eururo.2016.02.055. Epub 2016 Mar 7.
Perez-Lopez R, Lorente D, Blackledge MD, Collins DJ, Mateo J, Bianchini D, Omlin A, Zivi A, Leach MO, de Bono JS, Koh DM, Tunariu N. Volume of Bone Metastasis Assessed with Whole-Body Diffusion- weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology. 2016 Jul; 280(1):151-60. doi: 10.1148/radiol.2015150799. Epub 2016 Jan 25.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A’Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.
Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res. 2015 Oct 15;21(20):4586-96. doi: 10.1158/1078-0432.CCR-15-0584.
Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015 Jun;16(6):e279-92. doi: 10.1016/S1470-2045(15)70033-1.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21;161(5):1215-28. doi: 10.1016/j.cell.2015.05.001.
Pezaro C, Omlin A, Perez-Lopez R, Mukherji D, Attard G, Bianchini D, Lorente D, Parker C, Dearnaley D, de Bono JS, Sohaib A, Tunariu N. Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration- resistant prostate cancer. Clin Radiol. 2015 Apr;70(4):359-65. doi: 10.1016/j.crad.2014.05.104.
Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen S, de Bono J, Attard G. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer. 2014 Dec 9;111(12):2248-53. doi: 10.1038/bjc.2014.531.
Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. Eur Urol. 2015 Apr;67(4):795-802. doi: 10.1016/j.eururo.2014.10.027. Published on line: European Urology, 4 November 2014.